Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma

Medicine (United States)

Volumn 96, Issue 27, 2017, Pages

  Chen, Yu Hsiu ^a   Liu, Feng Cheng ^a   Hsu, Chang Hung ^b   Chian, Chih Feng ^b  

^a Tri Service General Hospital   (Mexico)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

case report; myasthenia gravis; nivolumab; squamous lung carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBON DIOXIDE; CD4 ANTIGEN; CD8 ANTIGEN; CHOLINERGIC RECEPTOR ANTIBODY; CISPLATIN; CREATINE KINASE; GEMCITABINE; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; MUSCLE ENZYME; NIVOLUMAB; PACLITAXEL; PYRIDOSTIGMINE; STEROID; TROPONIN I; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL RADIOGRAPHY; AGED; ARTICLE; BLOOD GAS ANALYSIS; BOTULISM; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CAUSE OF DEATH; CHEMORADIOTHERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIPLOPIA; DISEASE COURSE; DRUG EXPOSURE; DRUG INFUSION; DRUG TREATMENT FAILURE; DYSPHAGIA; ELECTROMYOGRAPHY; EYE MOVEMENT DISORDER; HOSPITAL ADMISSION; HUMAN; HYPERCAPNIA; HYPERSALIVATION; LIMB WEAKNESS; LYMPHADENOPATHY; MALE; MECHANICAL VENTILATOR; MEDICAL HISTORY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYASTHENIA; MYASTHENIA GRAVIS; MYOSITIS; NERVE CONDUCTION VELOCITY TEST; NEUROIMAGING; NEUROMUSCULAR JUNCTION DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARTIAL PRESSURE; PERIPHERAL LYMPHOCYTE; PHYSICAL EXAMINATION; PLASMA EXCHANGE; POLYNEUROPATHY; PRIORITY JOURNAL; PROVOCATION TEST; PTOSIS; RESPIRATORY FAILURE; SIDE EFFECT; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; THORACIC AORTA; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT REFUSAL; TREATMENT RESPONSE; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; COMPLICATION; DIFFERENTIAL DIAGNOSIS; FATALITY; LUNG NEOPLASMS;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; HUMANS; LUNG NEOPLASMS; MALE; MYASTHENIA GRAVIS;

EID: 85021866089     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000007350     Document Type: Article

References (16)

1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366: 2443-54.
2. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 2015;16:257-65.
3. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35.
4. Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma: Durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res 2014;2:15-8.
5. Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 2016;107:1055-8.
6. Bilen MA, Subudhi SK, Gao J, et al. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 2016;4:1.
7. Yoshioka M, Kambe N, Yamamoto Y, et al. Case of respiratory discomfort due to myositis after administration of nivolumab. J Dermatol 2015;42:1008-9.
8. Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 2015;52:307-8.
9. Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 2016;46:86-8.
10. Maeda O, Yokota K, Atsuta N, et al. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci 2016;78:119-22.
11. Polat P, Donofrio PD. Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle Nerve 2016;54: 507-1507.
12. Sciacca G, Nicoletti A, Rampello L, et al. Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve 2016;54:507-9.
13. Gilhus NE. Myasthenia gravis. N Engl J Med 2016;375:2570-81.
14. Liik M, Punga AR. Repetitive nerve stimulation often fails to detect abnormal decrement in acute severe generalized myasthenia gravis. Clin Neurophysiol 2016;127:3480-4.
15. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014;27:1-7.
16. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-42.